Related references
Note: Only part of the references are listed.Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Amy L. Shergold et al.
PHARMACOLOGICAL RESEARCH (2019)
PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
Shijie Xu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity
Zili Gu et al.
JOURNAL OF CONTROLLED RELEASE (2018)
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu et al.
NATURE (2018)
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
S. Chouaib et al.
ONCOGENE (2017)
Catalase-loaded cisplatin-prodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cancer
Rui Zhang et al.
BIOMATERIALS (2017)
Catalase-Loaded TaOx Nanoshells as Bio-Nanoreactors Combining High-Z Element and Enzyme Delivery for Enhancing Radiotherapy
Guosheng Song et al.
ADVANCED MATERIALS (2016)
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Andy J. Minn et al.
CELL (2016)
Targeting human melanoma neoantigens by T cell receptor gene therapy
Matthias Leisegang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Core-Shell MnSe@Bi2Se3 Fabricated via a Cation Exchange Method as Novel Nanotheranostics for Multimodal Imaging and Synergistic Thermoradiotherapy
Guosheng Song et al.
ADVANCED MATERIALS (2015)
Hypoxia-inducible factors in T lymphocyte differentiation and function. A Review in the Theme: Cellular Responses to Hypoxia
Jin-Hui Tao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2015)
Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia
Muhammad Zaeem Noman et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2015)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
Mahnaz Mellati et al.
DIABETES CARE (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin
Leila Arabi et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Nanoparticle-Based Immunotherapy for Cancer
Kun Shao et al.
ACS NANO (2015)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Drug delivery vehicles on a nano-engineering perspective
Betiana Felice et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2014)
Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?
Hisataka Kobayashi et al.
THERANOSTICS (2014)
Liposomal drug delivery systems: From concept to clinical applications
Theresa M. Allen et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Thomas F. Gajewski et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates
Christopher Southan et al.
DRUG DISCOVERY TODAY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature
Shujing Shi et al.
MEDICAL ONCOLOGY (2013)
The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel
Bing-Xiang Zhao et al.
BIOMATERIALS (2012)
Liposome-Encapsulated Anticancer Drugs: Still Waiting for the Magic Bullet?
R. Fanciullino et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage
G Cevc et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2004)